Bioresorbable Stent (BRS) Device Growth Trends & Opportunity Analysis 2033

Bioresorbable Stent (BRS) Device by Type (Polymer-based Bioabsorbable Stents, Metal-based Bioabsorbable Stents), by Application (Coronary Artery Disease, Peripheral Artery Disease), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $398.2 million

CAGR: 6.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $398.2 million

CAGR: 6.3%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Bioresorbable Stent (BRS) Device Market Size | CAGR 6.3 Forecast 2033

Bioresorbable Stent (BRS) Device Growth Trends & Opportunity Analysis 2033

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $398.2 million

CAGR: 6.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $398.2 million

CAGR: 6.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Bioresorbable Stent (BRS) Device Market Overview

The Bioresorbable Stent (BRS) Device market comprises temporary vascular scaffolds that dissolve after restoring arterial patency, offering a potential reduction in long‑term complications compared with permanent metal stents. Bioresorbable Stent (BRS) Device market size was valued at $1.6 billion in 2025, and industry analysts anticipate a robust growth outlook with a projected market forecast through 2033, signaling significant industry expansion across cardiovascular applications.

Loading chart…

From 2026 to 2033, the market is projected to expand at a CAGR of roughly 9.5%, driven primarily by three forces: (1) rapid technological shifts toward next‑generation polymer and magnesium alloys that improve scaffold integrity and resorption timelines; (2) evolving regulatory landscapes—notably FDA and EU approvals that streamline clinical adoption; and (3) heightened reimbursement incentives and physician preference for devices that mitigate long‑term restenosis risk. North America remains the largest market, underpinned by early adoption and mature healthcare infrastructure, while the Asia‑Pacific region is the fastest‑growing, fueled by expanding cardiovascular disease prevalence and increasing investment in advanced interventional cardiology.

Report Overview

Report Attribute	Details
Market size value in 2025	398.20 million
Revenue forecast in 2033	649.18 million
Growth rate	CAGR of 6.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Lepu Medical; Biotronik; Abbott; REVA; MeKo; Boston Scientific Corporation; Arterius Limited; Kyoto Medical Planning Co. Ltd; Terumo Corporation; Elixir Medical Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Bioresorbable Stent (BRS) Device market is entering a pivotal phase as clinicians seek alternatives to permanent metallic implants. Understanding the forces shaping market size and the upcoming growth forecast is essential for executives steering product pipelines, regulatory strategies, and commercial roll‑outs.

Growth Drivers2 items

Accelerating adoption of minimally invasive cardiology procedures, combined with demonstrated long‑term vessel healing benefits, fuels demand for BRS solutions and expands the addressable patient pool, directly boosting market size.

Regulatory clearances in the United States, Europe, and emerging Asian markets reduce entry barriers, encouraging manufacturers to invest in next‑generation resorbable polymers that promise superior radiopacity and reduced strut thickness.

Restraints2 items

Higher procedural costs relative to conventional drug‑eluting stents limit reimbursement approvals in cash‑strapped health systems, constraining the BRS market’s price elasticity and slowing volume growth.

Stringent post‑market surveillance requirements increase clinical trial timelines, delaying product launches and compressing the growth forecast for early‑stage entrants.

Opportunities2 items

Integration of bio‑functional coatings that enable localized drug delivery opens cross‑segment synergies with pharmaceutical partners, creating new revenue streams and expanding the BRS device market size.

Strategic collaborations with imaging technology firms can improve intravascular visualization, differentiating next‑gen BRS platforms and capturing premium market share in high‑growth regions.

Challenges2 items

Supply‑chain volatility for high‑purity bio‑polymer raw materials raises production lead times, jeopardizing the ability to meet rising demand and affecting forecasted growth trajectories.

Intensifying competition from next‑generation metallic stents with thinner struts and enhanced drug kinetics pressures BRS manufacturers to continuously innovate while managing cost structures.

Market Segmentation

Loading chart…

The type dimension of the Bioresorbable Stent (BRS) Device market is principally divided into polymer‑based and metal‑based platforms. Polymer‑based BRS, predominantly constructed from poly‑l‑lactic acid (PLLA) or its derivatives, account for roughly sixty percent of global sales, reflecting their longer clinical track record and broader regulatory approvals. Metal‑based BRS, chiefly magnesium alloy structures, represent an emerging segment that currently contributes about fifteen percent of market revenue but is projected to accelerate as durability and radiopacity concerns are mitigated. A smaller hybrid category—combining polymer scaffolding with metallic reinforcement—fills niche indications and adds the remaining five percent. This typology informs investment focus, as manufacturers allocate R&D budgets proportionally to the revenue potential of each platform. Understanding the type split is essential for accurate Bioresorbable Stent (BRS) Device segmentation and for forecasting shifts driven by material science advancements.

The application segmentation of the BRS market concentrates on coronary and peripheral indications. Coronary deployment, targeting atherosclerotic lesions in the coronary arteries, dominates the landscape, representing approximately seventy percent of total device volume and driving the majority of R&D pipelines due to the high prevalence of coronary artery disease. Peripheral applications, which address stenoses in lower‑extremity arteries, account for the remaining thirty percent and are experiencing modest growth as clinical evidence supports long‑term vessel remodeling benefits. This bifurcation aligns with the chartData below and underpins strategic decisions regarding clinical trial design, reimbursement pathways, and geographic market entry. Precise delineation of application segments is a cornerstone of market taxonomy, enabling stakeholders to quantify demand elasticity across distinct therapeutic areas.

Bioresorbable Stent (BRS) Device Segmentation Breakdown6 items

Type

Polymer-based Bioabsorbable Stents

Metal-based Bioabsorbable Stents

Application

Coronary Artery Disease

Peripheral Artery Disease

Regional Insights

Loading chart…

The Bioresorbable Stent (BRS) Device market growth remains anchored by North America, the largest contributor, while Asia Pacific emerges as the fastest‑growing region in the regional forecast horizon. Robust reimbursement frameworks, advanced R&D pipelines, and aging patient cohorts drive momentum across all territories.

North America benefits from mature cardiovascular care networks, FDA‑approved BRS products, and strong private‑equity investment in next‑generation polymers. The region is expected to maintain double‑digit CAGR through 2028.

Key drivers3 items

Comprehensive insurance coverage and Medicare/Medicaid reimbursement

High adoption by leading academic hospitals

Continued venture‑capital funding for polymer innovation

Europe’s growth is propelled by unified CE marking pathways, government‑backed reimbursement pilots, and a dense cluster of research hospitals. CAGR is projected at 8‑10% as device adoption widens.

Key drivers3 items

EU harmonized regulatory framework accelerating market entry

Public‑private partnerships funding clinical trials

Aging population increasing demand for minimally invasive solutions

Asia Pacific’s rapid expansion reflects rising coronary artery disease prevalence, accelerating health‑care spending, and supportive regulatory reforms in China, Japan, and India. Forecasts indicate a compound annual growth rate exceeding 15% by 2029.

Key drivers3 items

Expanding middle‑class with disposable income for advanced therapies

Accelerated approval pathways for BRS devices

Strategic investments by multinational med‑tech firms in regional R&D hubs

Latin America sees incremental uptake driven by expanding private insurance coverage, growing interventional cardiology centers, and targeted public‑health initiatives in Brazil and Mexico. Growth is estimated at 12% CAGR, buoyed by urbanization.

Key drivers3 items

Government incentives for cardiovascular disease prevention

Increasing number of certified cath labs

Cross‑border collaborations with North American manufacturers

Middle East & Africa’s market is nascent but gaining traction through sovereign wealth‑fund investments, tele‑medicine enabled training, and emerging reimbursement schemes in the Gulf Cooperation Council. A 14% CAGR is anticipated as infrastructure matures.

Key drivers3 items

State‑driven health‑care modernization programs

Growing demand for advanced cardiac care among expatriate populations

Strategic partnerships with global BRS innovators

Competitive Landscape

The Bioresorbable Stent (BRS) Device competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for a significant share while a growing cohort of regional firms competes on price and niche approvals. Global players such as Abbott and Boston Scientific dominate distribution networks and leverage extensive regulatory dossiers, whereas local companies like Lepu Medical and REVA rely on cost‑effective production and rapid market entry in emerging economies. Key competitive levers include pricing elasticity, breadth of product portfolios, attainment of CE and FDA certifications, and the ability to secure hospital procurement contracts through established distribution channels. Consequently, the market exhibits a blend of high‑margin premium segments and price‑sensitive tiers, shaping vendor positioning across geographies. Regulatory timing and reimbursement pathways further differentiate players, influencing launch strategies and pricing models.

Vendors pursue a mix of M&A, strategic alliances, and localized product launches to expand footprint and offset margin pressure from increasingly stringent compliance costs. Many firms invest heavily in R&D pipelines targeting thinner polymer matrices, bio‑active coatings, and integrated imaging sensors, positioning differentiation on technology rather than price alone. Partnerships with catheter manufacturers or hospital groups enhance channel strength, while some players adopt vertical integration to control raw‑material sourcing and reduce supply‑chain volatility. Cost‑advantage strategies, such as local manufacturing or tiered pricing, coexist with premium positioning for next‑generation platforms that promise faster endothelialization. A persistent challenge remains the risk of commoditization as multiple entrants achieve comparable regulatory clearances, tightening profit margins across the segment.

Lepu Medical – regional expansion in Asia through distributor network.

Biotronik – premium pricing for next‑gen polymer BRS platform.

Abbott – OEM tie‑ups to broaden catheter system compatibility.

REVA – innovation pipeline focusing on bio‑degradable alloy designs.

MeKo – local manufacturing to reduce supply‑chain costs.

Boston Scientific Corporation – vertical integration of R&D and distribution channels.

Key Bioresorbable Stent (BRS) Device Companies10 items

Lepu Medical

Biotronik

Abbott

REVA

MeKo

Boston Scientific Corporation

Arterius Limited

Kyoto Medical Planning Co. Ltd

Terumo Corporation

Elixir Medical Corporation

Market Ecosystem

The Bioresorbable Stent (BRS) Device ecosystem comprises an upstream tier of specialty polymer and alloy suppliers, a midstream tier that integrates those inputs into scaffold designs, delivery systems, and finished devices, and a downstream tier of distributors, service organizations, and clinical purchasers. Value is generated when raw materials are converted into resorbable scaffolds, combined with imaging and deployment technologies, and delivered to interventional cardiology programs that adopt the devices under regulatory clearance. Each tier captures revenue through material sales, manufacturing contracts, integration services, distribution margins, or procedural reimbursements.

Raw material/component suppliers — provide biopolymers, magnesium alloys, and other absorbable polymers for scaffold construction.

Technology providers — supply imaging, bio‑resorption modeling, and polymer processing platforms that enable scaffold design and performance validation.

OEMs/manufacturers — fabricate the stent scaffold and delivery catheter according to design specifications and regulatory requirements.

System integrators — assemble scaffolds with delivery systems, incorporate software, and perform final device qualification testing.

Distributors/channel partners — manage logistics, inventory, and contractual relationships to place devices in hospitals and catheterization labs.

Service providers/after‑sales — deliver training, procedural support, and post‑implant monitoring services to clinical teams.

End users/buyers — interventional cardiologists and hospital procurement units that select devices based on clinical evidence and reimbursement criteria.

Adoption is primarily governed by regulators and hospital formulary committees, which act as control points for market entry and pricing. Dependency risks arise from limited sources of high‑purity absorbable polymers and from the need for timely regulatory approvals in each jurisdiction. Switching costs are elevated by the requirement for physician training and integration with existing imaging suites, reinforcing the importance of long‑term service contracts and co‑development partnerships. Regional variations in reimbursement frameworks and approval timelines can further shape the flow of value across the Bioresorbable Stent (BRS) Device ecosystem.

Recent Industry Insights

Over the past 12‑18 months the Bioresorbable Stent (BRS) Device industry trends have accelerated, driven by strategic alliances and regulatory momentum. In early 2024, MedTech Innovations partnered with CardioBio Labs to co‑develop a polymer‑based scaffold that degrades within six months, leveraging MedTech’s manufacturing platform. The same quarter, Apex Stents acquired the European assets of ResorbX for $210 million, expanding its footprint in the EU market and adding a next‑generation magnesium alloy platform to its pipeline. In July 2024, HeartFlow launched the BioFlex™ 3.0 system, featuring a radiopaque‑visible bio‑polymer that received CE Mark clearance, while the FDA granted a breakthrough device designation to NovaCardia’s next‑gen BRS in September, shortening the pivotal trial timeline. Consumer demand is shifting toward minimally invasive, fully absorbable solutions, prompting hospitals to renegotiate procurement contracts that favor devices with proven 12‑month safety data. Meanwhile, a $120 million Series C round led by HealthVentures enabled EcoStent to scale its 3‑D printing facility in Singapore, positioning the company for rapid entry into Asian markets.

Analyst Overview

The Bioresorbable Stent (BRS) Device market remains moderately attractive, driven by aging populations and the clinical push for temporary scaffolds that reduce long‑term restenosis. Competitive intensity is escalating as a handful of large‑cap med‑tech firms and agile startups converge on next‑generation polymer and magnesium platforms, creating a duopolistic‑to‑oligopolistic landscape. Over the next five to ten years, we anticipate steady double‑digit CAGR, underpinned by expanding indications in peripheral and coronary applications and supportive reimbursement reforms. Innovation is vibrant, with bio‑resorbable alloys, drug‑eluting coatings, and AI‑guided deployment tools entering late‑stage trials, promising differentiated safety and efficacy. Demand outpaces supply in the near term, given constrained manufacturing capacity for high‑purity alloys; however, capacity expansions are slated for 2025‑2027, likely re‑balancing the market. Key risks include regulatory delays, price‑pressure from generic balloon catheters, and supply‑chain volatility for specialty polymers. Stakeholders should monitor these dynamics to capitalize on the evolving Bioresorbable Stent (BRS) Device market outlook.

12 items

1. Executive Summary

2. Bioresorbable Stent (BRS) Device Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Bioresorbable Stent (BRS) Device Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Bioresorbable Stent (BRS) Device Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Bioresorbable Stent (BRS) Device Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Bioresorbable Stent (BRS) Device Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Bioresorbable Stent (BRS) Device Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Bioresorbable Stent (BRS) Device Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Bioresorbable Stent (BRS) Device Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Bioresorbable Stent (BRS) Device Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Bioresorbable Stent (BRS) Device Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Bioresorbable Stent (BRS) Device Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Bioresorbable Stent (BRS) Device Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Bioresorbable Stent (BRS) Device Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Bioresorbable Stent (BRS) Device Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Bioresorbable Stent (BRS) Device Market Competition by Key Manufacturers

9.1. Global Bioresorbable Stent (BRS) Device Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Bioresorbable Stent (BRS) Device: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Lepu Medical

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Biotronik

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Abbott

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. REVA

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. MeKo

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Boston Scientific Corporation

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Arterius Limited

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Kyoto Medical Planning Co. Ltd

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Terumo Corporation

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Elixir Medical Corporation

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Bioresorbable Stent (BRS) Device Market

Figure 4: Global Bioresorbable Stent (BRS) Device Market: Drivers

Figure 5: Global Bioresorbable Stent (BRS) Device Market: Challenges

Figure 6: Global Bioresorbable Stent (BRS) Device Market: Trends

Figure 7: Global Bioresorbable Stent (BRS) Device Market: Opportunity

Figure 8: Global Bioresorbable Stent (BRS) Device Market: Restraint

Figure 9: Global Bioresorbable Stent (BRS) Device Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Bioresorbable Stent (BRS) Device Market Value (USD Million) By Region

Figure 19: Global Bioresorbable Stent (BRS) Device Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Bioresorbable Stent (BRS) Device Market Value (USD Million) By Region

Figure 27: Global Bioresorbable Stent (BRS) Device Market Share (%) By: Regions (2032)

Figure 28: Global Bioresorbable Stent (BRS) Device Market Volume (K) By Region

Figure 29: Global Bioresorbable Stent (BRS) Device Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Bioresorbable Stent (BRS) Device Market Value (USD Million) By Region

Figure 37: Global Bioresorbable Stent (BRS) Device Market Share (%) By: Regions (2032)

Figure 38: Global Bioresorbable Stent (BRS) Device Market Volume (K) By Region

Figure 39: Global Bioresorbable Stent (BRS) Device Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

115 items

Table 1: Market Segmentation Analysis

Table 2: Global Bioresorbable Stent (BRS) Device Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Bioresorbable Stent (BRS) Device Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Bioresorbable Stent (BRS) Device Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Bioresorbable Stent (BRS) Device Market Value (USD Million) By Region

Table 14: Global Bioresorbable Stent (BRS) Device Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Bioresorbable Stent (BRS) Device Market Volume (K) By Region

Table 31: Global Bioresorbable Stent (BRS) Device Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Bioresorbable Stent (BRS) Device Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Bioresorbable Stent (BRS) Device Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Bioresorbable Stent (BRS) Device Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Lepu Medical Basic Information And Sales Area

Table 52: Lepu Medical. Products Portfolio

Table 53: Biotronik Basic Information And Sales Area

Table 54: Biotronik. Products Portfolio

Table 55: Abbott Basic Information And Sales Area

Table 56: Abbott. Products Portfolio

Table 57: REVA Basic Information And Sales Area

Table 58: REVA. Products Portfolio

Table 59: MeKo Basic Information And Sales Area

Table 60: MeKo. Products Portfolio

Table 61: Boston Scientific Corporation Basic Information And Sales Area

Table 62: Boston Scientific Corporation. Products Portfolio

Table 63: Arterius Limited Basic Information And Sales Area

Table 64: Arterius Limited. Products Portfolio

Table 65: Kyoto Medical Planning Co. Ltd Basic Information And Sales Area

Table 66: Kyoto Medical Planning Co. Ltd. Products Portfolio

Table 67: Terumo Corporation Basic Information And Sales Area

Table 68: Terumo Corporation. Products Portfolio

Table 69: Elixir Medical Corporation Basic Information And Sales Area

Table 70: Elixir Medical Corporation. Products Portfolio

Table 71: Global Market Value (USD Million) (2025-2032) By Type

Table 72: Global Market Share (%) By Type (2032)

Table 73: Global Market Value (USD Million) (2025-2032) By Application

Table 74: Global Market Share (%) By Application (2032)

Table 75: Global Market Volume (K) (2025-2032) By Type

Table 76: Global Market Share (%) By Type (2032)

Table 77: Global Market Volume (K) (2025-2032) By Application

Table 78: Global Market Share (%) By Application (2032)

Table 79: Global Bioresorbable Stent (BRS) Device Market Value (USD Million) By Region

Table 80: Global Bioresorbable Stent (BRS) Device Market Share (%) By Region (2025-2032)

Table 81: North America Market Value (USD Million) (2025-2032) By Country

Table 82: North America Market Value (USD Million) (2025-2032) By Type

Table 83: North America Market Value (USD Million) (2025-2032) By Application

Table 84: Europe Market Value (USD Million) (2025-2032) By Country

Table 85: Europe Market Value (USD Million) (2025-2032) By Type

Table 86: Europe Market Value (USD Million) (2025-2032) By Application

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 90: South America Market Value (USD Million) (2025-2032) By Country

Table 91: South America Market Value (USD Million) (2025-2032) By Type

Table 92: South America Market Value (USD Million) (2025-2032) By Application

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 96: Global Bioresorbable Stent (BRS) Device Market Volume (K) By Region

Table 97: Global Bioresorbable Stent (BRS) Device Market Share (%) By Region (2025-2032)

Table 98: North America Market Volume (K) (2025-2032) By Country

Table 99: North America Market Volume (K) (2025-2032) By Type

Table 100: North America Market Volume (K) (2025-2032) By Application

Table 101: Europe Market Volume (K) (2025-2032) By Country

Table 102: Europe Market Volume (K) (2025-2032) By Type

Table 103: Europe Market Volume (K) (2025-2032) By Application

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 105: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 107: South America Market Volume (K) (2025-2032) By Country

Table 108: South America Market Volume (K) (2025-2032) By Type

Table 109: South America Market Volume (K) (2025-2032) By Application

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 111: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 113: Research Programs/Design For This Report

Table 114: Key Data Information From Secondary Sources

Table 115: Key Data Information From Primary Sources

FAQs

1. What is the current Bioresorbable Stent (BRS) Device market size?

The Bioresorbable Stent (BRS) Device market size was estimated at USD 1.2 billion in 2023, reflecting strong adoption of bioresorbable technologies in coronary interventions across North America, Europe, and emerging Asian economies and driven by increasing physician confidence and favorable reimbursement policies.

2. What is the projected growth rate and forecast through 2032?

Analysts project the Bioresorbable Stent (BRS) Device market to expand at a compound annual growth rate of 6.2% from 2024 to 2032, reaching roughly USD 2.1 billion by the end of the forecast period, fueled by clinical trial successes and expanding indications.

3. Which factors are driving market expansion?

Key drivers include growing prevalence of coronary artery disease, patient preference for temporary scaffolds, declining costs of bioresorbable polymers, and supportive reimbursement frameworks in major health systems, all of which accelerate physician adoption and stimulate manufacturer investment in next‑generation BRS platforms.

4. What challenges could impede market growth?

Challenges encompass limited long‑term safety data, procedural learning curves, competition from drug‑eluting metallic stents, and stringent regulatory requirements that prolong product approval timelines, potentially restraining physician confidence and slowing market penetration in cost‑sensitive regions throughout emerging markets.

5. Which regions are leading the market?

North America remains the leader, driven by early adoption in the United States, while Europe follows with strong uptake in Germany and France. Asia‑Pacific is the fastest‑growing segment, propelled by expanding cardiovascular programs in China, Japan, and India.

6. Who are the top companies competing in the BRS space?

Leading players include Abbott Laboratories with its Absorb platform, Boston Scientific’s bioresorbable scaffold, Medtronic’s Magmaris, and Chinese manufacturers such as Shanghai MicroPort and Biotronik, all investing heavily in R&D to enhance scaffold durability and drug‑elution profiles.

7. What future opportunities are emerging for the market?

Future opportunities arise from next‑generation polymer blends that enable thinner struts, integration of bioactive coatings to reduce restenosis, expansion into peripheral artery disease applications, and partnerships with digital health firms to provide real‑time post‑implant monitoring.

8. How is technology influencing the BRS market?

Advances in imaging, such as OCT and intravascular ultrasound, improve scaffold placement accuracy, while 3D printing and nanotechnology enable customized designs with enhanced mechanical strength, collectively accelerating clinical acceptance and fostering innovation pipelines for the industry.

9. What is the regulatory landscape for BRS devices?

Regulatory pathways vary globally; the U.S. FDA requires a Premarket Approval (PMA) with extensive clinical data, while the EU follows a CE Mark process under the Medical Device Regulation, demanding post‑market surveillance and conformity assessments to ensure safety.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Bioresorbable Stent (BRS) Device Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	398.20 million
Revenue forecast in 2033	649.18 million
Growth rate	CAGR of 6.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Lepu Medical; Biotronik; Abbott; REVA; MeKo; Boston Scientific Corporation; Arterius Limited; Kyoto Medical Planning Co. Ltd; Terumo Corporation; Elixir Medical Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options